Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. LLY has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
LLY stock price ended at $757.39 on Friday, after rising3.29%
The Eli Lilly and Co stock price increased by 3.29% on the last trading day (16 May 2025), rising from 740 to 757.39. Throughout the last trading session, the stock experienced a fluctuation of 2.89% , ranging from a day low of $737.55 to a day high of 758.87. The price has declined in 6 of the last 10 days, resulting in a total change of -8.04% during this period. On the last day, trading volume increase by -632.25K shares, with the rising prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 4.58M shares were traded, amounting to approximately 3.45B.
LLY Technical Signals
LLY(Eli Lilly and Co Corp) has 4 buy signals and 3 sell signals now. The current trend is consolidation starting from 2025-04-30. The total price change during this trend is -18.51%. Recently, the price has increased but the volume has decreased, indicating a potential warning signal. The average turnover of LLY over the last 5 trading days is 4.21B. Overall, the technical indicator signals lean more toward a Neutral outlook in the mid-term.
LLY Moving Average Analysis
Eli Lilly and Co's overall moving average trend leans more bearish as of Saturday, May 17, 2025, with 3 negative signals and 1 positive signal. In the mid-term, the SMA_20 being below the SMA_60 signals a strong bearish trend. There will be some resistance from the lines at $842.2236666666666, and $887.1086666666666. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $696.9936666666666, and $652.1086666666666. A break-down below any of these levels will issue sell signals.
LLY Short Selling Analysis
The short sale ratio of Eli Lilly and Co(LLY) as of 12 May 2025 is 13.39%, dropping from last trading day. With decreasing price from 734.57 to 755.57. The short sell activity indicate that short sellers may be experiencing short cover.
Technical Signal
Technical Signals Summary
Sell
3
Buy
4
Moving Average
Swing
Positive
Stock Price Above SMA_5
Short Term
Negative
SMA_5 Below SMA_20
Mid Term
Negative
SMA_20 Below SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
4 Bullish Signals
4 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
Indicators
Signal
Value
Meaning
Stochastic Oscillator %K (14, 3, 3)
STOCHk_14_3_3 < 20
7.957
Bullish
Commodity Channel Index (20 days, 0.015 constant)
CCI_20_0.015 < -100
-120.111
Bullish
Stochastic RSI %K (14, 14, 3, 3)
STOCHRSIk_14_14_3_3 < 20
7.449
Bullish
Williams %R (14 days)
WILLR_14 < -80
-90.184
Bullish
3 Bearish Signals
3 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
Indicators
Signal
Value
Meaning
Awesome Oscillator (5, 34)
AO_5_34 < 0
-48.915
Bearish
Momentum (10 days)
MOM_10 < 0
-61.57
Bearish
Moving Average Convergence Divergence (12, 26, 9)
MACD_12_26_9 < 0
-21.075
Bearish
LLY Price Prediction & Forecast by Similar Chart Analysis
Based on historical patterns and backtesting of stocks with similar movements to Eli Lilly and Co(LLY), our algorithm predicts LLY's 1-month price at $651.71, with an -11.28%downwardshift. Using a similarity score up to 92.57%and other factors, This forecast updates weekly, adjusting for significant deviations.
Similar Chart
The price prediction chart for Eli Lilly and Co (LLY.N) stock, as of Sunday, May 11, 2025 , forecasts a -11.28% change over the next month, based on its high correlation with OFLX.O stock patterns. The similarity between their price movements over the analyzed periods is 92.57%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
LLY
No Data
OFLX
Down: -11.28%Similarity: 92.57%
Name
Similarity
Up/Down
OFLX.O
92.57%
-11.28%
CVGW.O
92.31%
-24.48%
CVGI.O
92.29%
+23.56%
SKM.N
92.21%
-5.04%
FANG.O
92.00%
+30.47%
HI.N
91.76%
+12.09%
UBFO.O
91.51%
+5.41%
CF.N
91.44%
-1.43%
AM.N
91.19%
-4.76%
NRGV.N
91.10%
-23.79%
LLY Seasonality Analysis
Based on LLY's historical stock price data across all years, the probability of a positive return in May is54.55%, suggesting it maybe an ideal month to invest in LLY. In contrast,Juneoffers the highest probability of positive returns at90.00%, making it a potentially strong month for investment.
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying Eli Lilly and Co (LLY.N) stock in June has the highest probability of a positive return (90.00%), while February has the lowest probability (45.45%).
Performance Seasonality
The chart shows Eli Lilly and Co. (LLY)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
People Also Watch
FAQ
Should I buy Eli Lilly and Co (LLY.N) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. LLY has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
Which months have the highest win rate for buying Eli Lilly and Co (LLY.N) stock in a year?
The radar chart shows that buying Eli Lilly and Co (LLY.N) stock in June has the highest probability of a positive return (90.00%), while February has the lowest probability (45.45%).
How has Eli Lilly and Co. (LLY)'s stock price performed over the past three years?
LLY's stock price rose by 61.28% in 2023,increased by 31.00% in 2024, and went down by 2.66% in 2025.
Is LLY a buy based on overall technical signals summary?
LLY has 4 buy signals and 3 sell signals now. Overall the technical rating for LLY is Neutral . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of LLY.
What is the trend of Eli Lilly and Co (LLY)'s moving average?
Eli Lilly and Co's overall moving average trend leans more bearish as of May 17 2025, with 3 negative signals and 1 positive signal.
What is price prediction for LLY stock next month?
The price prediction chart for Eli Lilly and Co (LLY.N) stock, as of May 11 2025, forecasts a -11.28% change over the next month, based on its high correlation with OFLX stock patterns. The similarity between their price movements over the analyzed periods is 92.57%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for LLY Stock?
Eli Lilly's stock is expected to rise to **$850** by the end of 2025, driven by strong demand for its obesity drug Zepbound, which outperformed Novo Nordisk's Wegovy in a recent trial.
What is price prediction 2030 for LLY Stock?
### **Price Prediction for LLY Stock by 2030**
Eli Lilly (LLY) is expected to reach a stock price of **$1,200 to $1,500 by 2030**. This prediction is based on the company's strong pipeline, particularly the success of Zepbound and Mounjaro, which are outperforming competitors like Novo Nordisk's Wegovy. The growing demand for GLP-1 agonists in the obesity and diabetes markets, projected to exceed $150 billion annually, positions LLY for sustained growth. Analysts maintain a bullish outlook, with targets averaging around $950 currently, but long-term expansion into new therapeutic areas and continued innovation support a higher valuation by 2030.
{RATING:symbol=LLY, type=0}